| __timestamp | Genmab A/S | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 505679000 | 46425000 |
| Thursday, January 1, 2015 | 487656000 | 81491000 |
| Friday, January 1, 2016 | 660876000 | 94291000 |
| Sunday, January 1, 2017 | 874278000 | 121827000 |
| Monday, January 1, 2018 | 1431159000 | 160524000 |
| Tuesday, January 1, 2019 | 2386000000 | 200000000 |
| Wednesday, January 1, 2020 | 3137000000 | 275000000 |
| Friday, January 1, 2021 | 4181000000 | 328100000 |
| Saturday, January 1, 2022 | 5562000000 | 463800000 |
| Sunday, January 1, 2023 | 7630000000 | 565000000 |
| Monday, January 1, 2024 | 9748000000 | 731100000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical driver of innovation and growth. Over the past decade, Genmab A/S and Neurocrine Biosciences, Inc. have demonstrated contrasting trajectories in their R&D investments.
From 2014 to 2023, Genmab A/S has seen a staggering increase in its R&D budget, growing by over 1,400%, from approximately $500 million to $7.6 billion. This reflects Genmab's aggressive strategy to expand its research capabilities and pipeline. In contrast, Neurocrine Biosciences, Inc. has increased its R&D spending by around 1,100%, from $46 million to $565 million, indicating a more measured approach.
These trends highlight the varying strategies of biotech firms in allocating resources to innovation, with Genmab A/S leading the charge in R&D investment growth.
Comparing Innovation Spending: Amgen Inc. and Neurocrine Biosciences, Inc.
Research and Development Expenses Breakdown: Amgen Inc. vs Genmab A/S
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Research and Development: Comparing Key Metrics for Genmab A/S and Summit Therapeutics Inc.
Analyzing R&D Budgets: Genmab A/S vs Celldex Therapeutics, Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending